| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary molecular target of Biotin-PEG4-alkane-3',5'-cytidine-bisphosphate is not a specific protein receptor but rather nucleotide-binding proteins or enzymes that recognize cytidine or cytidine bisphosphate moieties. The biotin tag allows the compound to bind with high affinity to streptavidin or avidin proteins, making it a versatile probe for studying nucleotide interactions. It may also interact with polymerases or other enzymes that utilize nucleotide substrates in biochemical assays.
|
|---|---|
| ln Vitro |
In vitro, Biotin-PEG4-alkane-3',5'-cytidine-bisphosphate serves as a substrate or probe in various biochemical assays. The cytidine bisphosphate moiety can be recognized by enzymes such as nucleotide kinases or transferases, while the biotin tag enables capture or detection using streptavidin-conjugated reporters. The PEG4 linker provides flexibility and aqueous solubility, reducing steric hindrance during binding events. The compound can be used in pull-down assays, ELISA, or surface plasmon resonance (SPR) studies to investigate nucleotide-protein interactions.
|
| ln Vivo |
In vivo activity for Biotin-PEG4-alkane-3',5'-cytidine-bisphosphate is not typically characterized, as this compound is primarily used as a research tool for in vitro biochemical and cell-based applications rather than as a therapeutic agent. Its nucleotide structure and biotin modification may limit cellular permeability and systemic bioavailability. Any in vivo applications would likely involve local administration or use in specialized delivery systems for tracing or labeling purposes.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays for Biotin-PEG4-alkane-3',5'-cytidine-bisphosphate typically involve incubating the compound with purified nucleotide-binding proteins or enzymes in buffer systems. Binding interactions are detected using streptavidin-coated surfaces or beads to capture the biotinylated compound. For enzyme activity assays, the compound may be used as a substrate analog, and product formation is monitored by chromatographic or spectroscopic methods. The PEG4-alkane linker enhances solubility and reduces non-specific binding.
|
| Cell Assay |
In vitro cellular experiments using Biotin-PEG4-alkane-3',5'-cytidine-bisphosphate generally involve its application as a labeling reagent. Cells are incubated with the compound, and incorporation into cellular nucleotide pools or binding to cellular proteins is assessed. The biotin tag allows for subsequent detection using fluorescently labeled streptavidin or enzyme-conjugated streptavidin (e.g., HRP-streptavidin). The compound may also be used in nucleotide uptake studies or as a probe for studying nucleotide metabolism.
|
| Animal Protocol |
In vivo animal experiments are not commonly performed with Biotin-PEG4-alkane-3',5'-cytidine-bisphosphate due to its role as a research reagent rather than a therapeutic compound. If applied in animal models, it would likely be used as a tracing agent or for targeted delivery studies where the biotin moiety enables detection in tissue sections. The compound's stability in biological fluids and its distribution would need to be evaluated on a case-by-case basis.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Biotin-PEG4-alkane-3',5'-cytidine-bisphosphate are not well characterized, as the compound is not intended for therapeutic use. It has a molecular weight of 933.85 and a molecular formula of C33H57N7O18P2S. The compound is typically stored as a white to off-white solid at -20°C under nitrogen. In solvent, it is stable at -80°C for 6 months or at -20°C for 1 month under nitrogen. The PEG4 moiety contributes to its aqueous solubility.
|
| Toxicity/Toxicokinetics |
Toxicity data for Biotin-PEG4-alkane-3',5'-cytidine-bisphosphate are limited as it is a research reagent not intended for human use. Standard laboratory safety precautions should be followed when handling this compound. The compound contains a nucleotide analog and a biotin moiety, both of which are generally considered to have low toxicity in the context of in vitro applications. Researchers should consult the safety data sheet (SDS) for specific handling and disposal guidelines.
|
| References | |
| Additional Infomation |
Biotin-PEG4-alkane-3',5'-cytidine-bisphosphate (BPA-3',5'-pCp) is a specialized research tool identified by the synonyms BPA-3',5'-pCp. Its purity is typically ≥97%. The compound is described in GB2479833A as compound 6. It belongs to the category of nucleosides and their analogs. All products are for research use only and cannot be used for any clinical purposes.
|
| CAS # |
1340586-70-0
|
|---|---|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~107.08 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
